Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Rasmus Juul Kildemoes"'
Autor:
Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::482d3699b162aefaf4c47390e16cee4a
https://doi.org/10.1210/clinem/dgad095
https://doi.org/10.1210/clinem/dgad095
Autor:
Anders Juul, Philippe Backeljauw, Michael Højby, Masanobu Kawai, Rasmus Juul Kildemoes, Agnès Linglart, Nehama Zuckerman-Levin, Reiko Horikawa
Publikováno v:
Juul, A, Backeljauw, P, Højby, M, Kawai, M, Kildemoes, R J, Linglart, A, Zuckerman-Levin, N & Horikawa, R 2023, ' Somapacitan in children born small for gestational age : a multi-centre, open-label, controlled phase 2 study ', European Journal of Endocrinology, vol. 188, no. 1 . https://doi.org/10.1093/ejendo/lvac008
Objective Investigate efficacy, safety, and tolerability of 3 once-weekly somapacitan doses compared with daily growth hormone (GH) administration in short children born small for gestational age (SGA). Design Randomised, multi-centre, open-label, co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5f45ebf5d4efd1059177f8401f36b1
https://doi.org/10.1093/ejendo/lvac008
https://doi.org/10.1093/ejendo/lvac008
Autor:
Rasmus Juul Kildemoes, Christian Hollensen, Beverly M. K. Biller, Gudmundur Johannsson, Michael Højby Rasmussen
Publikováno v:
Folia Endocrinologica Japonica. 98:17-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36a5f6285db5ffe3afa2c62830caf19e
https://doi.org/10.1507/endocrine.98.s.update_17
https://doi.org/10.1507/endocrine.98.s.update_17
Autor:
Rasmus Juul Kildemoes, Steen H. Ingwersen, Andrea Navarria, Rune Viig Overgaard, Tine A. Bækdal
Publikováno v:
Clinical Pharmacokinetics
Objective The absorption, distribution and elimination of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist for treating type 2 diabetes, was investigated using a population pharmacokinetic model based on data from clinical ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1604a9f002d740b7673df58df99da9f
http://europepmc.org/articles/PMC8505367
http://europepmc.org/articles/PMC8505367
Autor:
Henrik Agersø, Michael Højby Rasmussen, Rasmus Juul Kildemoes, Birgitte Bentz Damholt, Theodoros Papathanasiou
Publikováno v:
Clinical Pharmacokinetics. 60:1217-1226
Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin®; Novo Nordisk A/S) are used to treat GH deficiency in children and adults, with much of the therapeutic effect mediated via the insulin-like growth factor-I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb517d2dafca592b570cab43f91af675
https://doi.org/10.1007/s40262-021-01011-3
https://doi.org/10.1007/s40262-021-01011-3
Autor:
Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa
Publikováno v:
The Journal of clinical endocrinology and metabolism. 107(12)
Context Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated in children with GH deficiency (GHD). Objective To demonstrate efficacy and safety of somapacitan vs daily GH. Methods REAL4 is a randomised, multinational, ope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62535a04077c6dbe6ad6e8c40ece869
https://pubmed.ncbi.nlm.nih.gov/36062966
https://pubmed.ncbi.nlm.nih.gov/36062966
Autor:
Anders Juul, Philippe Backeljauw, Michael Højby, Masanobu Kawai, Rasmus Juul Kildemoes, Agnès Linglart, Nehama Zuckerman-Levin, Reiko Horikawa
Publikováno v:
Journal of the Endocrine Society. 6:A646-A646
Treatment of persistent short stature in children born small for gestational age (SGA) requires daily growth hormone (GH) injections that can be burdensome for patients and caregivers. Once-weekly somapacitan is a long-acting GH currently in phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4694922f07cbc476a11882093e9825d1
https://doi.org/10.1210/jendso/bvac150.1336
https://doi.org/10.1210/jendso/bvac150.1336
Autor:
Paul Saenger, Tadej Battelino, Rasmus Juul Kildemoes, Michael Højby Rasmussen, Lars Sävendahl, Meryl Brod
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:e888-e889
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6aebb2d0211a09fb95ba53d75536a1b
https://doi.org/10.1210/clinem/dgab736
https://doi.org/10.1210/clinem/dgab736
Autor:
Theodoros, Papathanasiou, Henrik, Agersø, Birgitte Bentz, Damholt, Michael, Højby Rasmussen, Rasmus Juul, Kildemoes
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Once-daily injectable recombinant human growth hormone (GH) formulations (e.g. Norditropin®; Novo Nordisk A/S) are used to treat GH deficiency in children and adults, with much of the therapeutic effect mediated via the insu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30eff61f7c8943bca7bd6c7a539d3052
https://pubmed.ncbi.nlm.nih.gov/33864240
https://pubmed.ncbi.nlm.nih.gov/33864240
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Context Somapacitan is a long-acting growth hormone (GH) in development for once-weekly treatment of GH deficiency (GHD). Optimal monitoring of insulin-like growth factor-I (IGF-I) levels must account for weekly IGF-I fluctuations following somapacit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dfeaa41753a55942d5b7ce9ea8514f8
https://pubmed.ncbi.nlm.nih.gov/33524146
https://pubmed.ncbi.nlm.nih.gov/33524146